title: Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update.
abstract: Migraine as a highly disabling pain condition influences the daily activities of those affected, including children and adolescents. The pathomechanism of migraine is not fully understood, and the different types of prophylactic antimigraine drugs that are applied are not specific for migraine. There is a need for preventive treatment in the event of frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. The following pharmacological classes are recommended: antidepressants, antiepileptics, antihistamines, beta-adrenergic receptor blockers, and calcium ion channel antagonists, besides onabotulinum toxin A and nutraceuticals (butterbur). The most urgent goal as concerns pharmaceutical innovation is the development of pathomechanism-based antimigraine drugs and personalized therapy tailored to the children and adolescents.
authors.affiliation: Department of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u. 6, H-6725, Szeged, Hungary.
authors.forename: János
authors.initials: J
authors.lastname: Tajti
authors.affiliation: Department of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u. 6, H-6725, Szeged, Hungary.
authors.forename: Délia
authors.initials: D
authors.lastname: Szok
authors.affiliation: Department of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u. 6, H-6725, Szeged, Hungary.
authors.forename: Anett
authors.initials: A
authors.lastname: Csáti
authors.affiliation: Department of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u. 6, H-6725, Szeged, Hungary. vecsei.laszlo@med.u-szeged.hu.|Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged (MTA-SZTE Neuroscience Research Group), Semmelweis u. 6, H-6725, Szeged, Hungary. vecsei.laszlo@med.u-szeged.hu.
authors.forename: László
authors.initials: L
authors.lastname: Vécsei
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000700:Analgesics / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*
chemical_list: D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000927:Anticonvulsants; D000928:Antidepressive Agents; D002121:Calcium Channel Blockers
keywords: Antidepressants; Antiepileptics; Antihistamines; Beta-adrenergic receptor blockers; Butterbur; Calcium ion channel antagonists; Efficacy; Migraine; Onabotulinum toxin A; Pediatric; Prophylactic; Safety; Therapy; Tolerability